Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 54

1.

A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.

Duconge J, Ramos AS, Claudio-Campos K, Rivera-Miranda G, Bermúdez-Bosch L, Renta JY, Cadilla CL, Cruz I, Feliu JF, Vergara C, Ruaño G.

PLoS One. 2016 Jan 8;11(1):e0145480. doi: 10.1371/journal.pone.0145480. eCollection 2016.

2.

Synthesis and photocatalytic activity of TiO2 nanowires in the degradation of p-aminobenzoic acid: A comparative study with a commercial catalyst.

Soto-Vázquez L, Cotto M, Ducongé J, Morant C, Márquez F.

J Environ Manage. 2016 Feb 1;167:23-8. doi: 10.1016/j.jenvman.2015.11.006. Epub 2015 Nov 21.

PMID:
26610195
3.

Pharmacogenetics of healthy volunteers in Puerto Rico.

Claudio-Campos K, Orengo-Mercado C, Renta JY, Peguero M, García R, Hernández G, Corey S, Cadilla CL, Duconge J.

Drug Metabol Personal Ther. 2015 Dec 1;30(4):239-49. doi: 10.1515/dmpt-2015-0021.

PMID:
26501165
4.

Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials.

Duconge J, Cadilla CL, Seip RL, Ruaño G.

P R Health Sci J. 2015 Sep;34(3):175-7. No abstract available.

PMID:
26454897
5.

[Metabolic correction: a biochemical option against diseases].

Miranda-Massari JR, González MJ, Rodriguez-Gomez JR, Duconge J, Allende-Vigo MZ, Jiménez Ramirez FJ, Cintrón K, Ricart C, Zaragoza-Urdaz R, Berdiel MJ, Vázquez A.

Bol Asoc Med P R. 2015 Apr-Jun;107(2):60-6. Review. Spanish.

PMID:
26434086
6.

Metabolic Correction as a tool to improve diabetes type 2 management.

Miranda-Massari JR, Gonzalez MJ, Fernando AS, Cidre C, Paz IM, Charvel J, Martínez V, Duconge J, Aponte A, Ricart CM.

Bol Asoc Med P R. 2015 Apr-Jun;107(2):54-9.

PMID:
26434085
7.

Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation.

Duconge J, Ruaño G.

Pharmacogenomics. 2015;16(15):1685-8. doi: 10.2217/pgs.15.123. Epub 2015 Oct 2. No abstract available.

8.

Metabolic correction: a functional biochemical mechanism against disease--Part 2: mechanisms and benefits.

Miranda-Massari JR, González MJ, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, Hickey S, Vázquez A, Berdiel MJ, Cintrón K, Rodríguez-Gómez JR.

P R Health Sci J. 2015 Mar;34(1):9-13.

PMID:
25856871
9.

Metabolic correction: a functional biochemical mechanism against disease--Part 1: concept and historical background.

González MJ, Miranda-Massari JR, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, Cintrón K, Rodríguez-Gómez JR, Rosario G, Ricart C, Santiago-Cornier JA, Zaragoza-Urdaz R, Vázquez A, Hickey S, Jabbar-Berdiel M, Riordan N, Ichim T, Santiago O, Alvarado G, Vora P.

P R Health Sci J. 2015 Mar;34(1):3-8.

PMID:
25856870
10.

High Dose Intraveneous Vitamin C and Chikungunya Fever: A Case Report.

Gonzalez MJ, Miranda-Massari JR, Berdiel MJ, Duconge J, Rodríguez-López JL, Hunninghake R, Cobas-Rosario VJ.

J Orthomol Med. 2014;29(4):154-156.

11.

Pharmacokinetics of Rac inhibitor EHop-016 in mice by ultra-performance liquid chromatography tandem mass spectrometry.

Humphries-Bickley T, Castillo-Pichardo L, Corujo-Carro F, Duconge J, Hernandez-O'Farrill E, Vlaar C, Rodriguez-Orengo JF, Cubano L, Dharmawardhane S.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Feb 15;981-982:19-26. doi: 10.1016/j.jchromb.2014.12.021. Epub 2015 Jan 2.

PMID:
25594952
12.

Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.

Claudio-Campos K, Duconge J, Cadilla CL, Ruaño G.

Drug Metabol Personal Ther. 2015 Jun;30(2):87-105. doi: 10.1515/dmdi-2014-0023.

13.

Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans.

Valentín II, Rivera G, Nieves-Plaza M, Cruz I, Renta JY, Cadilla CL, Feliu JF, Seip RL, Ruaño G, Duconge J.

P R Health Sci J. 2014 Sep;33(3):97-104.

14.

CYP2D6's functional status associated with the length of hospitalization stay in psychiatric patients: a twist in the tale or evidence that matters?

Duconge J, Cadilla CL.

Biomark Med. 2013 Dec;7(6):913-4. doi: 10.2217/bmm.13.109. No abstract available.

15.

Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population.

Orengo-Mercado C, Nieves B, López L, Vallés-Ortiz N, Renta JY, Santiago-Borrero PJ, Cadilla CL, Duconge J.

J Pharmacogenomics Pharmacoproteomics. 2013 Mar 27;4(113). pii: 1000113.

16.

Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients.

Ramos AS, Seip RL, Rivera-Miranda G, Felici-Giovanini ME, Garcia-Berdecia R, Alejandro-Cowan Y, Kocherla M, Cruz I, Feliu JF, Cadilla CL, Renta JY, Gorowski K, Vergara C, Ruaño G, Duconge J.

Pharmacogenomics. 2012 Dec;13(16):1937-50. doi: 10.2217/pgs.12.171.

17.

'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine.

Duconge J, Ruaño G.

Pharmacogenomics. 2012 Jul;13(10):1097-100. doi: 10.2217/pgs.12.75. No abstract available.

18.

The bio-energetic theory of carcinogenesis.

Gonzalez MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T, Quintero-Del-Rio AI, Ortiz N.

Med Hypotheses. 2012 Oct;79(4):433-9. doi: 10.1016/j.mehy.2012.06.015. Epub 2012 Jul 17.

PMID:
22809841
19.

Preparation of hollow magnetite microspheres and their applications as drugs carriers.

Márquez F, Herrera GM, Campo T, Cotto M, Ducongé J, Sanz JM, Elizalde E, Perales O, Morant C.

Nanoscale Res Lett. 2012 Apr 10;7(1):210. doi: 10.1186/1556-276X-7-210.

20.

Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.

Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y, Gorowski K, Ruaño G, Duconge J.

Ann Pharmacother. 2012 Feb;46(2):208-18. doi: 10.1345/aph.1Q190. Epub 2012 Jan 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk